Shaw N J, Boivin C M, Crabtree N J
Department of Endocrinology, Birmingham Children's Hospital, Steelhouse Lane, Birmingham B4 6NH, UK.
Arch Dis Child. 2000 Aug;83(2):143-5. doi: 10.1136/adc.83.2.143.
To investigate the use of the aminobisphosphonate, disodium pamidronate, in children with vertebral osteoporosis.
Five children (aged 10-15 years) with vertebral osteoporosis who developed compression fractures in the thoracic and/or lumbar spine as a consequence of five different conditions, received treatment with intravenous disodium pamidronate in doses ranging from 0.5 to 12 mg/kg/y.
Each child had rapid pain relief following the first treatment, followed by large increments in lumbar spine bone density over one year; the change in bone density standard deviation score ranged from 0.5 to 2.5 with percentage increments of 26% to 54%.
Intravenous pamidronate appears to be a useful therapeutic option in childhood osteoporosis, but its use in children must still be regarded as experimental and therefore closely monitored.
研究氨基双膦酸盐帕米膦酸二钠在儿童椎体骨质疏松症中的应用。
五名10至15岁因五种不同情况导致胸椎和/或腰椎发生压缩性骨折的椎体骨质疏松症儿童，接受了剂量为0.5至12毫克/千克/年的静脉注射帕米膦酸二钠治疗。
每名儿童在首次治疗后疼痛迅速缓解，随后腰椎骨密度在一年内大幅增加；骨密度标准差分数变化范围为0.5至2.5，百分比增幅为26%至54%。
静脉注射帕米膦酸二钠似乎是儿童骨质疏松症的一种有效治疗选择，但在儿童中的应用仍应视为试验性的，因此需密切监测。
